- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07521007
Un essai clinique de phase 2b du YN001 chez des adultes atteints d'athérosclérose coronaire (PURIFY-TIMI 81)
Essai clinique de phase 2b randomisé, multicentrique, en double aveugle, en parallèle et contrôlé par placebo pour évaluer l'efficacité et la sécurité du YN001 chez les adultes atteints d'athérosclérose coronarienne
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jingmei Zhang, Master
- Numéro de téléphone: 0086 010 82599080
- E-mail: zhangjingmei@innovmedicine.com
Sauvegarde des contacts de l'étude
- Nom: Kaiqi Zong, Master
- Numéro de téléphone: 0086 010 82599080
- E-mail: zongkaiqi@innovmedicine.com
Lieux d'étude
-
-
New South Wales
-
Penrith, New South Wales, Australie, 2750
- Recrutement
- Cannopy Clinical Research
-
Contact:
- Karen Kaluhin, MD
- Numéro de téléphone: 0061 0491 276 512
- E-mail: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Australie, 4064
- Recrutement
- Core Research Group Pty Ltd.
-
Contact:
- David Colquhou, MD
- Numéro de téléphone: 614-1184-2788
- E-mail: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Australie, 3025
- Recrutement
- Canopy Clinical Research
-
Contact:
- Oscar Walsh, MD
- Numéro de téléphone: 0061 03 9968 7601
- E-mail: owalsh@canopycr.com.au
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Pas encore de recrutement
- St. Boniface Hospital
-
Contact:
- Shuangbo Liu
- Numéro de téléphone: 204-237-2793
- E-mail: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Canada, N5A 5A5
- Pas encore de recrutement
- London Health Sciences Centre
-
Contact:
- Habib Khan
- Numéro de téléphone: 519-663-3197
- E-mail: habib.khan@lhsc.on.ca
-
North York, Ontario, Canada, M6B 3H7
- Pas encore de recrutement
- North York Diagnostic and Cardiac Centre
-
Contact:
- Subodh Verma, MD
- Numéro de téléphone: 416-436-0244
- E-mail: subodh.verma@unityhealth.to
-
Toronto, Ontario, Canada, M5B 1W8
- Pas encore de recrutement
- St. Michael's Hospital
-
Contact:
- John Graham
- Numéro de téléphone: 416-864-6060
- E-mail: John.Graham@unityhealth.to
-
Vaughan, Ontario, Canada, L6A 4N9
- Pas encore de recrutement
- Cardiac Clinic
-
Contact:
- Navneet Singh
- Numéro de téléphone: 905-417-3001
- E-mail: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Canada, M5G 2N2
- Pas encore de recrutement
- Toronto General Hospital - University Health Network
-
Contact:
- Jacob Udell
- Numéro de téléphone: 416-340-4800
- E-mail: jay.udell@utoronto.ca
-
-
-
-
An
-
Hefei, An, Chine, 230022
- Recrutement
- The First Affiliated Hospital of Anhui Medical Unversity
-
Contact:
- Jianlong Wang, MD
- Numéro de téléphone: 0086-13681292304
- E-mail: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, Chine, 230001
- Recrutement
- Anhui Provincial Hospital
-
Contact:
- Kangyu Chen, MD
- Numéro de téléphone: 0086 18056005099
- E-mail: ustccky@126.com
-
Chercheur principal:
- Kangyu Chen, MD
-
Sous-enquêteur:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100035
- Recrutement
- Beijing Jishuitan Hospital
-
Chercheur principal:
- Wei Liu, MD
-
Contact:
- Qingwei Ji, MD
- Numéro de téléphone: 0086 18376642655
- E-mail: jqwl24@163.cou
-
Chercheur principal:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, Chine, 100029
- Recrutement
- Anzhen Hospital
-
Contact:
- Yuyang Liu, MD
- Numéro de téléphone: 0086 010-64456488
- E-mail: liuyy803803@163.com
-
Chercheur principal:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, Chine, 101100
- Pas encore de recrutement
- Beijing Luhe Hospital
-
Contact:
- Guangyao Zhai, MD
- Numéro de téléphone: +86 1069543901
- E-mail: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350001
- Recrutement
- Fujian Medical University Union Hospital
-
Contact:
- Mingfang Ye, MD
- Numéro de téléphone: 0086 13960818759
- E-mail: xieheyemingfang@163.com
-
Chercheur principal:
- Mingfang Ye, MD
-
Sous-enquêteur:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, Chine, 730030
- Recrutement
- The Second Hospital & Clinical Medical School Lanzhou University
-
Contact:
- Feng Bai, MD
- Numéro de téléphone: 0086-13609363049
- E-mail: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510080
- Recrutement
- Guangdong Provincial People's Hospital
-
Contact:
- Ning Tan, MD
- E-mail: tanning100@126.com
-
Contact:
- Numéro de téléphone: 0086-13903073651
- E-mail: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, Chine, 163316
- Recrutement
- Daqing People's Hospital
-
Contact:
- Shu Zhang
- Numéro de téléphone: +86-459-6612898
- E-mail: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, Chine, 150001
- Recrutement
- The First Affiliated Hospital of Harbin Medical University
-
Contact:
- Lu Fu, MD
- Numéro de téléphone: 0086 137 9668 4968
- E-mail: fuluyidayi@163.com
-
Chercheur principal:
- Lu Fu, MD
-
Chercheur principal:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, Chine, 430071
- Recrutement
- Zhongnan Hospital of Wuhan University
-
Contact:
- Xiaorong Hu, MD
- Numéro de téléphone: 0086 15927681634
- E-mail: huzrzn@whu.edu.cn
-
Chercheur principal:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, Chine, 410008
- Recrutement
- The Second Xiangya Hospital fo Central South University
-
Contact:
- Xinqun Hu, MD
- Numéro de téléphone: 0086-13307313627
- E-mail: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, Chine, 130033
- Recrutement
- The First Hospital of Jilin University
-
Chercheur principal:
- Qian Tong, MD
-
Contact:
- Qian Tong, MD
- Numéro de téléphone: 0086 13074337289
- E-mail: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, Chine, 110015
- Recrutement
- The People's Hospital of Liaoning Province
-
Chercheur principal:
- Ying Liu, MD
-
Contact:
- Ying Liu, MD
- Numéro de téléphone: 0086 13840065379
- E-mail: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710068
- Recrutement
- Shaanxi Provincial People's Hospital
-
Contact:
- Xiling Shou, MD
- Numéro de téléphone: 0086 18966700335
- E-mail: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, Chine
- Recrutement
- Central Hospital Affiliated to Shandong First Medicial University
-
Contact:
- Guohai Su, MD
- Numéro de téléphone: 0086 19953193319
- E-mail: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200032
- Recrutement
- Fudan University-Zhongshan Hospital
-
Chercheur principal:
- Junbo Ge, MD
-
Contact:
- Junbo Ge, MD
- Numéro de téléphone: 021-64041990
- E-mail: ge.junbo@zs-hospital.sh.cn
-
Sous-enquêteur:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, Chine, 200001
- Recrutement
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Contact:
- Jun Bu, MD
- Numéro de téléphone: 0086 13601958108
- E-mail: pujun310@hotmail.com
-
Chercheur principal:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- West China Hospital of Sichuan University
-
Contact:
- Yong He, MD
- Numéro de téléphone: 0086 18980602038
- E-mail: zznnyeah@163.com
-
Chercheur principal:
- Yong He, MD
-
Chengdu, Sichuan, Chine, 610072
- Recrutement
- Sichuan Provincial People's Hospital
-
Contact:
- Jianhong Tao, DM
- Numéro de téléphone: 86-189 8183 8875
- E-mail: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300211
- Recrutement
- The Second Hospital of Tianjin Medical University
-
Contact:
- Tong Liu, MD
- Numéro de téléphone: 0086 13902183163
- E-mail: liutongdoc@126.com
-
Chercheur principal:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, Chine, 300121
- Recrutement
- Tianjin People's Hospital
-
Chercheur principal:
- Zhuhua Yao, MD
-
Contact:
- Zhuhua Yao, MD
- Numéro de téléphone: 0086 13902199877
- E-mail: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310006
- Recrutement
- Zhejiang Provincial People's Hospital
-
Contact:
- Lihong Wang, MD
- Numéro de téléphone: 0086-13666690598
- E-mail: wlhhz@hotmail.com
-
Suzhou, Zhejiang, Chine, 215006
- Recrutement
- The First Affiliated Hospital of Soochow University
-
Contact:
- Tingbo Jiang, MD
- Numéro de téléphone: 0086-18906201122
- E-mail: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, Chine, 325000
- Recrutement
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Contact:
- lianpin Wu, MD
- E-mail: 198019@wzhealth.com
-
-
-
-
Alabama
-
Huntsville, Alabama, États-Unis, 35801-4312
- Recrutement
- Heart Center Research, LLC
-
Contact:
- Walter Haught, MD
- Numéro de téléphone: 256-519-8472
- E-mail: hhaught@theheartcenter.md
-
-
California
-
Covina, California, États-Unis, 91740
- Pas encore de recrutement
- Thrive Clinical Research Group, LLC
-
Contact:
- Sami Hayek
- Numéro de téléphone: 818-280-4220
- E-mail: samihayek82@hotmail.com
-
Contact:
- E-mail: shayek@foothillcardiology.com
-
Lincoln, California, États-Unis, 95648
- Pas encore de recrutement
- Clinical Trials Research
-
Contact:
- Jeffrey Wayne, MD
- Numéro de téléphone: 916-434-8230
- E-mail: jwaynemd@ctrsites.com
-
Los Alamitos, California, États-Unis, 90720
- Pas encore de recrutement
- University of California Irvine Medical Center - Cardiovascular Center
-
Contact:
- Arnold Seto
- Numéro de téléphone: 562-598-3200
- E-mail: arnold.seto@va.gov
-
Stanford, California, États-Unis, 94305-2200
- Pas encore de recrutement
- Stanford Health Care General Cardiology
-
Contact:
- Fahim Abbasi, MD
- Numéro de téléphone: 650-723-6459
- E-mail: fahim@stanford.edu
-
Torrance, California, États-Unis, 90502-2006
- Recrutement
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Contact:
- Matthew Budoff, MD
- Numéro de téléphone: 310-222-3641
- E-mail: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, États-Unis, 33434
- Pas encore de recrutement
- Flourish Research - Boca Raton
-
Contact:
- Richard Goldman
- Numéro de téléphone: 561-756-8206
- E-mail: rgoldman@flourishresearch.com
-
Hialeah, Florida, États-Unis, 33016-1895
- Recrutement
- New Generation of Medical Research, LLC.
-
Contact:
- Karelia Ruiz
- Numéro de téléphone: 305-828-9100
- E-mail: kareliar@ngmresearch.com
-
St. Petersburg, Florida, États-Unis, 33709
- Recrutement
- HCA Florida Heart Institute
-
Contact:
- Robert Sanchez, MD
- Numéro de téléphone: 727-490-2100
- E-mail: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30303-3049
- Pas encore de recrutement
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Contact:
- Modele Ogunniyi
- Numéro de téléphone: 404-616-4440
- E-mail: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, États-Unis, 83642
- Pas encore de recrutement
- St. Luke's Clinic - Idaho Cardiology Associates
-
Contact:
- Brian Nolan
- Numéro de téléphone: 208-322-1680
- E-mail: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, États-Unis, 62781
- Pas encore de recrutement
- Southern Illinois University School of Medicine
-
Contact:
- Abdul Hafiz, MD
- Numéro de téléphone: 217-545-8000
- E-mail: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66211-1215
- Recrutement
- Midwest Heart & Vascular Specialists, LLC
-
Contact:
- Stephen Bloom, MD
- Numéro de téléphone: 913-253-3000
- E-mail: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110-1032
- Recrutement
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Contact:
- Farhan Katchi, MD
- Numéro de téléphone: 314-362-1291
- E-mail: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, États-Unis, 27607
- Pas encore de recrutement
- NC Heart and Vascular Research, LLC
-
Contact:
- Mohit Pasi
- Numéro de téléphone: 919-784-2300
- E-mail: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, États-Unis, 27104-3520
- Pas encore de recrutement
- Javara Inc. - Wake Forest University Health Sciences
-
Contact:
- Michael Shapiro, MD
- Numéro de téléphone: 336-713-7251
- E-mail: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- Pas encore de recrutement
- The Christ Hospital
-
Contact:
- Mark Berlacher, MD
- Numéro de téléphone: 513-585-1777
- E-mail: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73135
- Pas encore de recrutement
- South Oklahoma Heart Research, LLC
-
Contact:
- Naeem Tahirkheli
- Numéro de téléphone: 405-628-6865
- E-mail: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, États-Unis, 17011
- Recrutement
- Capital Area Research, LLC - Camp Hill
-
Contact:
- Venkatesh Nadar, MD
- Numéro de téléphone: 717-695-8722
- E-mail: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, États-Unis, 79106
- Recrutement
- PharmaTex Research, LLC
-
Contact:
- David Brabham
- Numéro de téléphone: 806-355-2581
- E-mail: dgbrabham@hotmail.com
-
Carrollton, Texas, États-Unis, 75010
- Pas encore de recrutement
- Pulse Care Heart and Vascular
-
Contact:
- Kiran Kumar Mangalpally
- Numéro de téléphone: 214-407-8640
- E-mail: trials@stryderesearch.com
-
Tomball, Texas, États-Unis, 77375
- Pas encore de recrutement
- DM Clinical Research - Dallas
-
Contact:
- Mustafa Mandviwala
- Numéro de téléphone: 346-550-9559
- E-mail: drmandviwala.ns@dmclinical.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Expérimental: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Comparateur placebo: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Délai: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Délai: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Délai: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Délai: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Délai: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Délai: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Délai: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Délai: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Délai: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Délai: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Délai: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Délai: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Délai: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Délai: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- YN001-203
- IND 157167 (Identificateur de registre: Beijing Inno Medicine Co., Ltd.)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .